Epigenomic marks indicating enhancer activity at the 5q22 locus.

<p>Histone marks in samples from the ROADMAP Epigenomics Project at the enhancer overlapping the lead SNP rs9885413 in heart tissue (left ventricle) and in tissues with evidence of an active enhancer at the locus. Histone marks are monomethylation (H3K4Me1) of the fourth residue (lysine) and acetylation of the 27th residue (H3K27Ac) of histone H3. Positions refer to NCBI build 36.</p

Association of genetic polymorphisms with HF mortality.

<p>Association of genetic polymorphisms with HF mortality.</p

Characteristics of cohorts in stage 1.

<p>Characteristics of cohorts in stage 1.</p

Sample characteristics and association results for P155L (rs139709573) in <i>TM2D3</i> in the two Icelandic AGES cohorts.

<p>Sample characteristics and association results for P155L (rs139709573) in <i>TM2D3</i> in the two Icelandic AGES cohorts.</p

Kaplan-Meier survival curves for <i>TM2D3</i>.

<p>Curves are based on incident data only. There was no evidence of bias due to competing risk of death (<b>Supporting results in <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1006327#pgen.1006327.s001" target="_blank">S1 Text</a></b>).</p

Regional plots for the association of SNPs with MI in the region of <i>QKI</i>.

<p>Regional plots for the association of SNPs with MI in the region of <i>QKI</i>.</p

Association of the known SNPs for coronary artery disease with incident MI and CHD in Stage I.

<p>Association of the known SNPs for coronary artery disease with incident MI and CHD in Stage I.</p